TY - CHAP M1 - Book, Section TI - Diabetes Mellitus A1 - Trujillo, Jennifer A1 - Haines, Stuart A2 - DiPiro, Joseph T. A2 - Yee, Gary C. A2 - Haines, Stuart T. A2 - Nolin, Thomas D. A2 - Ellingrod, Vicki L. A2 - Posey, L. Michael PY - 2023 T2 - DiPiro’s Pharmacotherapy: A Pathophysiologic Approach, 12th Edition AB - Update SummaryMay, 2023The following sections, tables, and figures were updated:Extensive revisions were made throughout the chapter based on the new recommendations from the 2023 American Diabetes Association Standards of Care to the following sections:Approach to treatmentStepwise addition of medicationsComplications and comorbiditiesTirzepatide, a dual glucose-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, was approved by the FDA in 2022. Information regarding tirzepatide has been added in multiple sections and Table 94-10. SN - PB - McGraw Hill CY - New York, NY Y2 - 2024/03/28 UR - accesspharmacy.mhmedical.com/content.aspx?aid=1205562736 ER -